These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18206365)

  • 21. Health system responses to the Women's Health Initiative findings on estrogen and progestin: organizational response.
    Hartsfield CL; Connelly MT; Newton KM; Andrade SE; Wei F; Buist DS
    J Natl Cancer Inst Monogr; 2005; (35):113-5. PubMed ID: 16287896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progesterone, progestins, pregnancy and breast cancer risk.
    Ferretti G
    Breast Cancer Res Treat; 2007 Jul; 103(3):373-4. PubMed ID: 17063269
    [No Abstract]   [Full Text] [Related]  

  • 23. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
    Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
    Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
    Simoncini T; Genazzani AR
    Climacteric; 2010 Feb; 13(1):22-33. PubMed ID: 19938948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progestins and breast cancer risk.
    Campagnoli C; Biglia N; Giai M; Sismondi P
    Zentralbl Gynakol; 1997; 119 Suppl 2():38-42. PubMed ID: 9361393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought.
    Speroff L
    Menopause; 2008; 15(2):393-400. PubMed ID: 17925662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The breast cancer "plunge" after initial publication of the WHI results: an alternative explanation.
    Simon JA; Nahum GG; Stanislaw H; Gaines T
    Maturitas; 2010 Jul; 66(3):277-84. PubMed ID: 20471761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progestogens in postmenopausal hormone therapy and the risk of breast cancer.
    Lambrinoudaki I
    Maturitas; 2014 Apr; 77(4):311-7. PubMed ID: 24485796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Where are we with postmenopausal hormone therapy in 2005?
    Lam PM; Chung TK; Haines C
    Gynecol Endocrinol; 2005 Nov; 21(5):248-56. PubMed ID: 16373243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer.
    Birrell SN; Butler LM; Harris JM; Buchanan G; Tilley WD
    FASEB J; 2007 Aug; 21(10):2285-93. PubMed ID: 17413000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Be careful of what you wish for: putting the WHI Estrogen/Progestin and HERS II Trials in perspective.
    Randolph JF;
    Medscape Womens Health; 2002; 7(4):7. PubMed ID: 12466739
    [No Abstract]   [Full Text] [Related]  

  • 35. Breast cancer risk in the WHI study: the problem of obesity.
    Kuhl H
    Maturitas; 2005 May; 51(1):83-97. PubMed ID: 15883113
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinician's review of the WHI-related literature.
    Speroff L
    Int J Fertil Womens Med; 2004; 49(6):252-67. PubMed ID: 15751264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of breast cancer with progestins: critical assessment of current data.
    Santen RJ
    Steroids; 2003 Nov; 68(10-13):953-64. PubMed ID: 14667988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Timing of hormone therapy influences breast cancer risk.
    Harv Womens Health Watch; 2011 Apr; 18(8):7. PubMed ID: 21544975
    [No Abstract]   [Full Text] [Related]  

  • 39. Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue.
    Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
    Gynecol Endocrinol; 2009 Dec; 25(12):807-15. PubMed ID: 19906000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
    Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
    Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.